Female sexual dysfunction in androgenetic alopecia: Case-control study

dc.authorid0000-0002-5007-8143
dc.authorid0000-0003-1470-5952
dc.authorscopusid55753628300
dc.authorscopusid55749960900
dc.authorscopusid57194558922
dc.authorscopusid55647897100
dc.authorscopusid23977731600
dc.authorscopusid57216014831
dc.authorscopusid56841316400
dc.authorwosidAkbulut, Tugba Özkök/AAM-5899-2021
dc.authorwosidAkbulut, Mehmet Fatih/N-3886-2019
dc.authorwosidAkbas, Alpaslan/AAX-5617-2020
dc.contributor.authorSancak, Eyüp Burak
dc.contributor.authorOğuz, Sevilay
dc.contributor.authorAkbulut, Tuğba
dc.contributor.authorUludağ, Ayşegül
dc.contributor.authorAkbaş, Alpaslan
dc.contributor.authorKurt, Ömer
dc.contributor.authorAkbulut, Mehmet Fatih
dc.date.accessioned2022-05-11T14:36:59Z
dc.date.available2022-05-11T14:36:59Z
dc.date.issued2016
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.description.abstractIntroduction: We sought to evaluate the association of female sexual dysfunction (FSD) with androgenetic alopecia (AGA) and metabolic syndrome (MetS) in premenopausal women. Methods: From December 2013 to June 2015, we performed a case-control, prospective study of 115 patients with AGA and 97 age-matched control patients without AGA from among premenopausal women who visited dermatology clinics of the two reference hospitals. Comprehensive history, anthropometric measurements, and questionnaire administration were performed for each of the total of 212 women. The Female Sexual Function Index (FSFI) was used to assess the key dimensions of female sexual function. AGA was assessed and graded by an experienced dermatologist according to Ludwig's classification. The MetS assessment was made according to the NCEP-ATP III criteria. Results: In univariate analysis, age, weight, waist circumference, hip circumference, waist-to-hip ratio, body mass index (BMI), AGA, MetS, cardiovascular event, marital status, hypertension, high fasting plasma glucose, high triglyceride, large waist, total testosterone, and free testosterone were associated with presence of FSD. In logistic regression analysis, age (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.13. 1.30; p<0.001), AGA (OR 3.42, 95% CI 1.31. 8.94; p= 0.017), MetS (OR 5.39, 95% CI 1.34. 21.62; p= 0.012), and free testosterone (OR 0.18, 95% CI 0.09. 0.37; p< 0.001) were independently associated with FSD. Conclusions: Our study suggests that age, AGA, MetS, and free testosterone may have strong impact on sexual function in premenopausal women. Further studies with population-based and longitudinal design should be conducted to confirm this finding.
dc.identifier.doi10.5489/cuaj.3582
dc.identifier.endpageE256
dc.identifier.issn1911-6470
dc.identifier.issn1920-1214
dc.identifier.issue45511en_US
dc.identifier.pmid28255417
dc.identifier.scopus2-s2.0-84978173620
dc.identifier.scopusqualityQ2
dc.identifier.startpageE251
dc.identifier.urihttps://doi.org/10.5489/cuaj.3582
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8515
dc.identifier.volume10
dc.identifier.wosWOS:000382528100008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKurt, Ömer
dc.language.isoen
dc.publisherCanadian Urological Association
dc.relation.ispartofCuaj-Canadian Urological Association Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMiddle-Aged Women
dc.subjectMetabolic Syndrome
dc.subjectInsulin-Resistance
dc.subjectRisk-Factors
dc.subjectIndex Fsfi
dc.subjectTestosterone
dc.subjectPrevalence
dc.subjectAssociation
dc.subjectTherapy
dc.subjectMen
dc.titleFemale sexual dysfunction in androgenetic alopecia: Case-control study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
8515.pdf
Boyut:
745.18 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text